Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40569
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLandi, Antonio-
dc.contributor.authorHeg, Dik-
dc.contributor.authorFrigoli, Enrico-
dc.contributor.authorVRANCKX, Pascal-
dc.contributor.authorWindecker, Stephan-
dc.contributor.authorSiegrist, Patrick-
dc.contributor.authorCayla, Guillaume-
dc.contributor.authorWlodalczak, Adrian-
dc.contributor.authorCook, Stephane-
dc.contributor.authorGomez-Blazquez, Ivan-
dc.contributor.authorFeld, Yair-
dc.contributor.authorSeung-Jung, Park-
dc.contributor.authorMates, Martin-
dc.contributor.authorLotan, Chaim-
dc.contributor.authorGunasekaran, Sengottuvelu-
dc.contributor.authorNanasato, Mamoru-
dc.contributor.authorDas , Rajiv-
dc.contributor.authorKelbaek, Henning-
dc.contributor.authorTeiger, Emmanuel-
dc.contributor.authorEscaned, Javier-
dc.contributor.authorIshibashi, Yuki-
dc.contributor.authorMontalescot, Gilles-
dc.contributor.authorMatsuo, Hitoshi-
dc.contributor.authorDebeljacki, Dragan-
dc.contributor.authorSmits, Pieter C.-
dc.contributor.authorValgimigli, Marco-
dc.date.accessioned2023-07-13T07:46:38Z-
dc.date.available2023-07-13T07:46:38Z-
dc.date.issued2023-
dc.date.submitted2023-07-06T13:27:39Z-
dc.identifier.citationJACC-Cardiovascular Interventions, 16 (7) , p. 798 -812-
dc.identifier.urihttp://hdl.handle.net/1942/40569-
dc.description.abstractBACKGROUND Clinical outcomes and treatment selection after completing the randomized phase of modern trials, investigating antiplatelet therapy (APT) after percutaneous coronary intervention (PCI), are unknown. OBJECTIVES The authors sought to investigate cumulative 15-month and 12-to-15-month outcomes after PCI during routine care in the MASTER DAPT trial. METHODS The MASTER DAPT trial randomized 4,579 high bleeding risk patients to abbreviated (n = 2,295) or standard (n = 2,284) APT regimens. Coprimary outcomes were net adverse clinical outcomes (NACE) (all-cause death, myocardial infarction, stroke, and BARC 3 or 5 bleeding); major adverse cardiac and cerebral events (MACCE) (all-cause death, myocardial infarction, and stroke); and BARC type 2, 3, or 5 bleeding. RESULTS At 15 months, prior allocation to a standard APT regimen was associated with greater use of intensified APT; NACE and MACCE did not differ between abbreviated vs standard APT (HR: 0.92 [95% CI: 0.76-1.12]; P = 0.399 and HR: 0.94 [95% CI: 0.76-1.17]; P = 0.579; respectively), as during the routine care period (HR: 0.81 [95% CI: 0.50-1.30]; P = 0.387 and HR: 0.74 [95% CI: 0.43-1.26]; P = 0.268; respectively). BARC 2, 3, or 5 was lower with abbreviated APT at 15 months (HR: 0.68 [95% CI: 0.56-0.83]; P = 0.0001) and did not differ during the routine care period. The treatment effects during routine care were consistent with those observed within 12 months after PCI. CONCLUSIONS At 15 months, NACE and MACCE did not differ in the 2 study groups, whereas the risk of major or clinically relevant nonmajor bleeding remained lower with abbreviated compared with standard APT. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020) (J Am Coll Cardiol Intv 2023;16:798-812) (c) 2023 by the American College of Cardiology Foundation.-
dc.description.sponsorshipThe study was sponsored by the European Cardiovascular Research Institute, a nonprofit organization, and received grant support from Terumo. Drs Heg and Frigoli are with CTU Bern, University of Bern, which has a staff policy of not accepting honoraria or consultancy fees. However, CTU Bern is involved in design, conduct, or analysis of clinical studies funded by not-for-profit and for-profit organizations. In particular, pharmaceutical and medical device companies provide direct funding to some-
dc.language.isoen-
dc.publisherELSEVIER SCIENCE INC-
dc.subject.otherKEY WORDS antiplatelet therapy-
dc.subject.otherdual antiplatelet therapy-
dc.subject.otherhigh bleeding risk-
dc.subject.otherpercutaneous coronary intervention-
dc.titleAbbreviated or Standard Antiplatelet Therapy in HBR Patients Final 15-Month Results of the MASTER-DAPT Trial-
dc.typeJournal Contribution-
dc.identifier.epage812-
dc.identifier.issue7-
dc.identifier.spage798-
dc.identifier.volume16-
local.format.pages15-
local.bibliographicCitation.jcatA1-
dc.description.notesValgimigli, M (corresponding author), Ente Osped Cantonale, Cardioctr Ticino Inst, Via Tesserete 48, CH-6900 Lugano, Switzerland.-
dc.description.notesmarco.valgimigli@eoc.ch-
local.publisher.placeSTE 800, 230 PARK AVE, NEW YORK, NY 10169 USA-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.identifier.doi10.1016/j.jcin.2023.01.366-
dc.identifier.pmid37045500-
dc.identifier.isi000996512200001-
local.provider.typewosris-
local.description.affiliation[Landi, Antonio; Frigoli, Enrico; Valgimigli, Marco] Univ Svizzera Italiana, Cardioctr Ticino Inst, Ente Osped Cantonale EOC, Lugano, Switzerland.-
local.description.affiliation[Heg, Dik; Frigoli, Enrico] Univ Bern, CTU Bern, Bern, Switzerland.-
local.description.affiliation[Vranckx, Pascal] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium.-
local.description.affiliation[Windecker, Stephan] Bern Univ Hosp, Dept Cardiol, Bern, Switzerland.-
local.description.affiliation[Siegrist, Patrick] HerzZentrum Hirslanden Zurich, Zurich, Switzerland.-
local.description.affiliation[Cayla, Guillaume] Univ Montpellier, Nimes Univ Hosp, Dept Cardiol, Nimes, France.-
local.description.affiliation[Wlodalczak, Adrian] Miedziowe Ctr Zdrow, Dept Cardiol, Lubin, Poland.-
local.description.affiliation[Cook, Stephane] Fribourg Hosp Cantonal, Dept Cardiol, Fribourg, Switzerland.-
local.description.affiliation[Gomez-Blazquez, Ivan] Hosp Univ 12 Octubre, Dept Cardiol, Madrid, Spain.-
local.description.affiliation[Feld, Yair] Rambam Healthcare Campus, Cardiol Dept, Haifa, Israel.-
local.description.affiliation[Seung-Jung, Park] Sungkyunkwan Univ, Dept Internal Med, Sch Med, Seoul, South Korea.-
local.description.affiliation[Mates, Martin] Na Homolce Hosp, Dept Cardiol, Cardiovasc Ctr, Prague, Czech Republic.-
local.description.affiliation[Lotan, Chaim] Hebrew Univ Jerusalem, Fac Med, Heart Ctr, Hadassah Med Ctr, Jerusalem, Israel.-
local.description.affiliation[Gunasekaran, Sengottuvelu] Apollo Main Hosp, Dept Cardiol, Chennai, India.-
local.description.affiliation[Nanasato, Mamoru] Sakakibara Heart Inst, Dept Cardiol, Tokyo, Japan.-
local.description.affiliation[Das, Rajiv] Freeman Rd Hosp, Cardiothorac Ctr, Newcastle Upon Tyne, Tyne & Wear, England.-
local.description.affiliation[Kelbaek, Henning] Zealand Univ Hosp, Dept Cardiol, Roskilde, Denmark.-
local.description.affiliation[Teiger, Emmanuel] Univ Hosp Henri Mondor, Dept Cardiol, Creteil, France.-
local.description.affiliation[Escaned, Javier] Hosp Clin San Carlos IDISSC, Dept Cardiol, Madrid, Spain.-
local.description.affiliation[Escaned, Javier] Univ Complutense Madrid, Madrid, Spain.-
local.description.affiliation[Ishibashi, Yuki] St Marianna Univ, Dept Internal Med, Div Cardiol, Sch Med, Kawasaki, Japan.-
local.description.affiliation[Montalescot, Gilles] Sorbonne Univ, Pitie Salpetriere Hosp, ACTION Grp, Grp Hosp, Paris, France.-
local.description.affiliation[Matsuo, Hitoshi] Gifu Heart Ctr, Dept Cardiovasc Med, Gifu, Japan.-
local.description.affiliation[Debeljacki, Dragan] Inst Cardiovasc Dis, Dept Cardiol, Sremaska Kamen, Serbia.-
local.description.affiliation[Smits, Pieter C.] Maasstad Hosp, Dept Cardiol, Rotterdam, Netherlands.-
local.description.affiliation[Valgimigli, Marco] Univ Italian Switzerland, Dept Biomed Sci, Lugano, Switzerland.-
local.uhasselt.internationalyes-
item.fullcitationLandi, Antonio; Heg, Dik; Frigoli, Enrico; VRANCKX, Pascal; Windecker, Stephan; Siegrist, Patrick; Cayla, Guillaume; Wlodalczak, Adrian; Cook, Stephane; Gomez-Blazquez, Ivan; Feld, Yair; Seung-Jung, Park; Mates, Martin; Lotan, Chaim; Gunasekaran, Sengottuvelu; Nanasato, Mamoru; Das , Rajiv; Kelbaek, Henning; Teiger, Emmanuel; Escaned, Javier; Ishibashi, Yuki; Montalescot, Gilles; Matsuo, Hitoshi; Debeljacki, Dragan; Smits, Pieter C. & Valgimigli, Marco (2023) Abbreviated or Standard Antiplatelet Therapy in HBR Patients Final 15-Month Results of the MASTER-DAPT Trial. In: JACC-Cardiovascular Interventions, 16 (7) , p. 798 -812.-
item.contributorLandi, Antonio-
item.contributorHeg, Dik-
item.contributorFrigoli, Enrico-
item.contributorVRANCKX, Pascal-
item.contributorWindecker, Stephan-
item.contributorSiegrist, Patrick-
item.contributorCayla, Guillaume-
item.contributorWlodalczak, Adrian-
item.contributorCook, Stephane-
item.contributorGomez-Blazquez, Ivan-
item.contributorFeld, Yair-
item.contributorSeung-Jung, Park-
item.contributorMates, Martin-
item.contributorLotan, Chaim-
item.contributorGunasekaran, Sengottuvelu-
item.contributorNanasato, Mamoru-
item.contributorDas , Rajiv-
item.contributorKelbaek, Henning-
item.contributorTeiger, Emmanuel-
item.contributorEscaned, Javier-
item.contributorIshibashi, Yuki-
item.contributorMontalescot, Gilles-
item.contributorMatsuo, Hitoshi-
item.contributorDebeljacki, Dragan-
item.contributorSmits, Pieter C.-
item.contributorValgimigli, Marco-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
crisitem.journal.issn1936-8798-
crisitem.journal.eissn1876-7605-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
Abbreviated or Standard Antiplatelet.pdfPeer-reviewed author version1.39 MBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

4
checked on May 14, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.